ES2153033T3 - Inhibicion de la 5-lipooxigenasa. - Google Patents
Inhibicion de la 5-lipooxigenasa.Info
- Publication number
- ES2153033T3 ES2153033T3 ES95918121T ES95918121T ES2153033T3 ES 2153033 T3 ES2153033 T3 ES 2153033T3 ES 95918121 T ES95918121 T ES 95918121T ES 95918121 T ES95918121 T ES 95918121T ES 2153033 T3 ES2153033 T3 ES 2153033T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halo
- cyano
- alkylene
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
NUEVOS COMPUESTOS QUE TIENEN LA CAPACIDAD DE INHIBIR UNA ENZIMA DE 5-LIPOXIGENASA Y QUE TIENEN LA FORMULA (I) Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE AR{SUP,1} ES UNA ESTRUCTURA HETEROCICLICA QUE SE SELECCIONA DE IMIDAZOLILO, PIRROLILO, PIRAZOLILO, 1,2,3-TRIAZOLILO, 1,2,4-TRIAZOLILO, INDOLILO, INDAZOLILO Y BENCIMIDAZOLILO, LA CUAL ESTA UNIDA A X{SUP,1} A TRAVES DE UN ATOMO DE NITROGENO DE ANILLO, Y LA CUAL PUEDE SER OPCIONALMENTE SUSTITUIDA CON UNO O DOS SUSTITUYENTES SELECCIONADOS DE HALO, HIDROXIDO, CIANO, AMINO, ALQUILO C{SUB,14} Y SIMILARES; X{SUP,1} ES UNA UNION DIRECTA O ALQUILENO C{SUB,1-4}; AR{SUP,2} ES FENILENO OPCIONALMENTE SUSTITUIDO CON HALO, HIDROXIDO, CIANO, AMINO Y SIMILARES; X{SUP,2} ES -A-X- O X-A- EN DONDE A ES UNA UNION DIRECTA O ALQUILENO C{SUB,1-4} Y X ES OXI, TIO, SULFINILO O SULFONILO; AR{SUP,3} ES FENILENO, PIRIDILENO, TIENILENO, FURILENO, OXAZOLILENO O TIAZOLILENO OPCIONALMENTE SUSTITUIDOS CON UNO O DOS SUSTITUYENTES SELECCIONADOS DE HALO, HIDROXIDO, CIANO, AMINO, ALQUILO C{SUB,14} Y SIMILARES; R{SUP,1} Y R{SUP,2} SON CADA UNO ALQUILO C{SUB,14}, O JUNTOS FORMAN UN GRUPO DE FORMULA -D{SUP,1}-Z-D{SUP,2}- QUE JUNTO CON EL ATOMO DE CARBONO AL QUE ESTA INCORPORADO DEFINE UN ANILLO QUE TIENE DE 3 A 8 ATOMOS, EN DONDE D{SUP,1} Y D{SUP,2} SON ALQUILENO C{SUB,1-4} Y Z ES UNA UNION DIRECTA U OXI, TIO, SULFINILO, SULFONILO O VINILENO, Y D{SUP,1} Y D{SUP,2} PUEDEN SER SUSTITUIDOS POR ALQUILO C{SUB,1-3}; E Y ES CONR{SUP,3}R{SUP,4}, CN, C(()R{SUP,3}())=N-OR{SUP,4}, COOR{SUP,3}, COR{SUP,3} O CSNR{SUP,3}R{SUP,4}, EN DONDE R{SUP,3} Y R{SUP,4} SON CADA UNO H O ALQUILO C{SUB,1-4}. ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO O MEJORA DE ENFERMEDADES INFLAMATORIAS, ALERGIA Y ENFERMEDADES CARDIOVASCULARES EN MAMIFEROS Y COMO EL INGREDIENTE ACTIVO EN COMPOSICIONES FARMACEUTICAS PARA TRATAMIENTO DE DICHAS CONDICIONES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9401747 | 1994-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2153033T3 true ES2153033T3 (es) | 2001-02-16 |
Family
ID=14098722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95918121T Expired - Lifetime ES2153033T3 (es) | 1994-10-18 | 1995-05-29 | Inhibicion de la 5-lipooxigenasa. |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP0787127B1 (es) |
| JP (1) | JP3032579B2 (es) |
| CN (1) | CN1093536C (es) |
| AT (1) | ATE198474T1 (es) |
| AU (1) | AU681520B2 (es) |
| BG (1) | BG61768B1 (es) |
| CA (1) | CA2202057C (es) |
| CO (1) | CO4480026A1 (es) |
| CZ (1) | CZ287350B6 (es) |
| DE (1) | DE69519804T2 (es) |
| DK (1) | DK0787127T3 (es) |
| ES (1) | ES2153033T3 (es) |
| FI (1) | FI971632A (es) |
| GR (1) | GR3035471T3 (es) |
| HU (1) | HU221543B (es) |
| IL (1) | IL115581A (es) |
| LV (1) | LV11468B (es) |
| MY (1) | MY114680A (es) |
| NO (1) | NO314629B1 (es) |
| NZ (1) | NZ285163A (es) |
| PE (1) | PE49196A1 (es) |
| PL (1) | PL180104B1 (es) |
| RU (1) | RU2136666C1 (es) |
| SI (1) | SI9500392A (es) |
| SK (1) | SK281577B6 (es) |
| TR (1) | TR199501274A2 (es) |
| TW (1) | TW411339B (es) |
| UA (1) | UA45312C2 (es) |
| WO (1) | WO1996011911A1 (es) |
| YU (1) | YU65995A (es) |
| ZA (1) | ZA958748B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239285B1 (en) | 1998-02-06 | 2001-05-29 | Pfizer Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| US6194585B1 (en) * | 1998-12-22 | 2001-02-27 | Pfizer Inc. | Process for preparing 5-lipoxygenase inhibitors |
| US6346624B1 (en) * | 1999-08-31 | 2002-02-12 | Pfizer Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| US6344563B1 (en) | 1999-08-31 | 2002-02-05 | Timothy Norris | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| SG87145A1 (en) * | 1999-08-31 | 2002-03-19 | Pfizer Prod Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| ES2398093T3 (es) * | 2000-03-24 | 2013-03-13 | Euro-Celtique S.A. | Pirazoles, triazoles y tetrazoles sustituidos con arilo como bloqueantes de los canales de sodio |
| CA2444735C (en) * | 2001-04-20 | 2012-10-23 | Novozymes A/S | Lipoxygenase |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| UA92833C2 (en) | 2006-11-27 | 2010-12-10 | Пфайзер Продактс Инк. | Pyrazole analogues |
| EA201000703A1 (ru) * | 2007-11-26 | 2010-12-30 | Пфайзер Инк. | Производные пиразола в качестве ингибиторов 5-lo |
| CN104144920A (zh) * | 2012-02-28 | 2014-11-12 | 皮拉马尔企业有限公司 | 作为gpr促效剂的苯基烷酸衍生物 |
| HRP20220331T1 (hr) | 2018-03-08 | 2022-05-13 | Incyte Corporation | Spojevi aminopirazin diola kao inhibitori pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0462830B1 (en) * | 1990-06-21 | 1995-10-18 | Zeneca Limited | Cyclic ether derivatives |
| IE913866A1 (en) * | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
| EP0505122A1 (en) * | 1991-03-21 | 1992-09-23 | Zeneca Limited | Alpha, alpha-dialkylbenzyl derivatives |
| EP0540165A1 (en) * | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
| AU685122B2 (en) * | 1993-06-14 | 1998-01-15 | Pfizer Inc. | Imidazole lipoxygenase inhibitors |
-
1994
- 1994-10-18 SK SK1287-95A patent/SK281577B6/sk unknown
-
1995
- 1995-05-29 JP JP8513058A patent/JP3032579B2/ja not_active Expired - Fee Related
- 1995-05-29 NZ NZ285163A patent/NZ285163A/en unknown
- 1995-05-29 DE DE69519804T patent/DE69519804T2/de not_active Expired - Fee Related
- 1995-05-29 PL PL95319727A patent/PL180104B1/pl not_active IP Right Cessation
- 1995-05-29 AT AT95918121T patent/ATE198474T1/de not_active IP Right Cessation
- 1995-05-29 HU HU9701853A patent/HU221543B/hu not_active IP Right Cessation
- 1995-05-29 EP EP95918121A patent/EP0787127B1/en not_active Expired - Lifetime
- 1995-05-29 CZ CZ19971177A patent/CZ287350B6/cs not_active IP Right Cessation
- 1995-05-29 WO PCT/IB1995/000408 patent/WO1996011911A1/en active IP Right Grant
- 1995-05-29 ES ES95918121T patent/ES2153033T3/es not_active Expired - Lifetime
- 1995-05-29 CN CN95195926A patent/CN1093536C/zh not_active Expired - Fee Related
- 1995-05-29 DK DK95918121T patent/DK0787127T3/da active
- 1995-05-29 RU RU97106099/04A patent/RU2136666C1/ru not_active IP Right Cessation
- 1995-05-29 AU AU24174/95A patent/AU681520B2/en not_active Ceased
- 1995-05-29 CA CA002202057A patent/CA2202057C/en not_active Expired - Fee Related
- 1995-09-12 TW TW084109522A patent/TW411339B/zh not_active IP Right Cessation
- 1995-10-02 CO CO95045652A patent/CO4480026A1/es unknown
- 1995-10-12 IL IL11558195A patent/IL115581A/xx not_active IP Right Cessation
- 1995-10-13 UA UA95104510A patent/UA45312C2/uk unknown
- 1995-10-16 MY MYPI95003103A patent/MY114680A/en unknown
- 1995-10-17 PE PE1995282113A patent/PE49196A1/es not_active Application Discontinuation
- 1995-10-17 ZA ZA958748A patent/ZA958748B/xx unknown
- 1995-10-17 YU YU65995A patent/YU65995A/sh unknown
- 1995-10-17 SI SI9500392A patent/SI9500392A/sl unknown
- 1995-10-17 LV LVP-95-313A patent/LV11468B/en unknown
- 1995-10-18 TR TR95/01274A patent/TR199501274A2/xx unknown
- 1995-10-18 BG BG100070A patent/BG61768B1/bg unknown
-
1997
- 1997-04-17 NO NO19971773A patent/NO314629B1/no unknown
- 1997-04-17 FI FI971632A patent/FI971632A/fi not_active IP Right Cessation
-
2001
- 2001-02-23 GR GR20010400310T patent/GR3035471T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2153033T3 (es) | Inhibicion de la 5-lipooxigenasa. | |
| EP0629622A4 (es) | ||
| FI70888B (fi) | Analogifoerfarande foer framstaellning av terapeutiskt anvaendbara | |
| DE60017582D1 (de) | Tricyclische derivate der pyrazolcarbonsäure, ihre herstellung und sie enthaltende pharmazeutische zubereitungen | |
| NO913750D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater. | |
| KR920701167A (ko) | 약제학적 활성 화합물 | |
| MY128063A (en) | Aromatic heterocyclic compound as antiinflammatory agents | |
| DK0418845T3 (da) | Pyrazolderivater, fremgangsmåder til fremstilling deraf og farmaceutisk præparat omfattende samme | |
| IL88901A (en) | Substituted 1,2,3-triazole, 1,2,4-triazole, pyrazole and pyrrole derivatives, their preparation and pharmaceutical compositions containing them | |
| CA2440222A1 (en) | Triazolopyridines as anti-inflammatory agents | |
| CA2171637A1 (en) | Substituted Azaheterocyclecarboxylic Acids | |
| CZ20013522A3 (cs) | Sloučeniny inhibující adhezi buněk vykazující protizánětlivé a imunosupresivní účinky | |
| US4652582A (en) | Antiinflammatory-2-halo-4,5-diarylpyrroles | |
| RU97106099A (ru) | Ингибиторы 5-липоксигеназы | |
| MX9702814A (es) | Inhibidores de la 5-lipoxigenasa. | |
| CA2160140A1 (en) | Cycloalkylhydroxyureas and Their Use As Lipoxygenase Inhibitors | |
| CA2232267A1 (en) | Novel imidazole lipoxygenase inhibitors | |
| EP0420086A3 (en) | Pyrimidoindole derivatives and processes for preparation thereof | |
| CA2244695A1 (en) | Cyclic amic acid derivatives | |
| TH23886B (th) | ตัวขัดขวาง 5-ลิปอกซีจีเนส | |
| TH23886A (th) | ตัวขัดขวาง 5-ลิปอกซีจีเนส | |
| KR20050023428A (ko) | 신규 인돌린 화합물 및 그것의 의약 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Grant refused |
Effective date: 19991001 |
|
| FG2A | Definitive protection |
Ref document number: 787127 Country of ref document: ES |